Search
for

    Sort by

    Research 721–750 of 1000+

    1. Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study Frontiers in Public Health · 2024
    2. LB1040 Machine learning-based predictive model with routine blood work identifies moderate-severe alopecia areata Journal of Investigative Dermatology · 2024
    3. Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children Frontiers in immunology · 2024
    4. JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience e_Buah · 2024
    5. Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse Clinical and experimental dermatology · 2024
    6. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis Frontiers in pharmacology · 2024
    7. Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report 2024
    8. Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis Clinical and experimental dermatology · 2024
    9. The effect of low-level laser therapy on severe acute respiratory syndrome coronavirus-2 infected cells 2024
    10. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    11. Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study Journal of Cosmetic Dermatology · 2023
    12. Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy Skin · 2023
    13. Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran Journal of Cosmetic Dermatology · 2023
    14. <i>DSG4</i> Gene Variants as a Cause of Hypotrichosis in the Child with Severe Atopic Dermatitis: Clinical Case Вопросы современной педиатрии · 2023
    15. 164 Epigenetic and transcriptional profiling of PBMCs in mild and severe alopecia areata using single-cell RNA-Seq and ATAC-Seq Journal of Investigative Dermatology · 2023
    16. THU471 Resolution Of Elevated Alkaline Phosphatase After Joint Replacement In Severe Osteoarthritis Journal of the Endocrine Society · 2023
    17. 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata Journal of The American Academy of Dermatology · 2023
    18. 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry Journal of the American Academy of Dermatology · 2023
    19. 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2 Journal of The American Academy of Dermatology · 2023
    20. Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients Anais Brasileiros de Dermatologia · 2023
    21. Efficacy and Safety of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial Dermatology and Therapy · 2023
    22. Diagnosis and differential diagnosis of tertiary androgenetic alopecia with severe alopecia areata based on high‐resolution MRI Skin Research and Technology · 2023
    23. Diphenylcyclopropenone and platelet‐rich plasma in the management of severe or recalcitrant alopecia areata Journal of cosmetic dermatology · 2023
    24. P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2 British Journal of Dermatology · 2023
    25. BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience British Journal of Dermatology · 2023
    26. EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata Value in Health · 2022
    27. Myxedema Coma and Acute Hepatopathy in a Dog with Severe Atherosclerosis Case Reports in Veterinary Medicine · 2021
    28. Faculty Opinions recommendation of Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2020
    29. A Cross-Sectional Study Of The Association Between Skin Tags And Vascular Risk Factors In Patients With Severe And Complicated Obesity Research Square (Research Square) · 2020
    30. Patients with Compound Heterozygous Mutations in Forkhead Box N1 have a Severe Immunodeficiency while Maintaining Normal Skin and Hair Development 2017